We read with interest the article by Ning Zhang et al. [
[1]
]. The author conducted a prospective, random, controlled trials (RCTs) to compare
the clinical effects and safety of Shenfu injection (SFI) in patients with sepsis
or septic shock, which found that SFI should improve cellular immunity but not clinical
outcome. We congratulate the authors for this successful article, however, some issues
should be discussed to avoid misinterpretations.Abbreviations:
SFI (Shenfu injection), RCTs (random, controlled trials)Keywords
To read this article in full you will need to make a payment
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of Emergency MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Shenfu injection for improving cellular immunity and clinical outcome in patients with sepsis or septic shock.Am J Emerg Med. 2016; 35: 1-6https://doi.org/10.1016/j.ajem.2016.09.008
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA. 2016; 315: 801-810https://doi.org/10.1001/jama.2016.0287
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.Intensive Care Med. 2003; 31: 1250https://doi.org/10.1007/s00134-003-1662-x
- The appropriateness of some common procedures for testing the equality of two independent binomial populations.Am Stat. 1988; 42: 198-202https://doi.org/10.1080/00031305.1988.10475563
- Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016.Intensive Care Med. 2017; 43: 1-74https://doi.org/10.1097/CCM.0000000000002255
Article Info
Publication History
Published online: November 20, 2018
Accepted:
November 20,
2018
Received:
November 12,
2018
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
